Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Vascular anomaly" patented technology

A vascular anomaly is a kind of birthmark caused by a disorder of the vascular development, although it is not always present at birth. A vascular anomaly is a localized defect in blood vessels that can affect each part of the vasculature (capillaries, arteries, veins, lymphatics or a combination of these). These defects are characterized by an increased number of vessels and vessels that are both enlarged and sinuous. Some vascular anomalies are congenital and therefore present at birth, others appear within weeks to years after birth and others are acquired by trauma or during pregnancy. Inherited vascular anomalies are also described and often present with a number of lesions that increase with patients’ age. Vascular anomalies can also be a part of a syndrome and, occasionally, they can be acquired by trauma. The estimated prevalence of vascular anomalies is 4.5%. Vascular anomalies can occur throughout the whole body (skin, bone, liver, intestines, i.e.), but in 60% of patients vascular anomalies are localized in the head and neck region. Vascular anomalies can present in various ways. Vascular anomalies that are situated deep below the skin, appear blue and are often called cavernous. Superficial vascular anomalies appear as red-coloured stains and are associated with vascular anomalies affecting the dermis. Historically, vascular anomalies have been labeled with descriptive terms, according to the food they resembled (port wine, strawberry, cherry, salmon patch). This imprecise terminology has caused diagnostic confusion, blocked communication and even caused incorrect treatment, as it does not differentiate between various vascular anomalies. However, in 1982, Mulliken introduced a classification that replaced these descriptive terms and gave direction to the management of various vascular anomalies. This classification, based on clinical features, natural history and cellular characteristics, divides vascular anomalies into two groups: vascular tumors and vascular malformations. Although the appearance of both vascular tumors and vascular malformations can resemble, there are important differences between both.

Endovascular apparatus

InactiveUS7255711B2Same resultStentsOcculdersVascular Skin TumorIntravascular device
Percutaneous treatment of aortic aneurysms and like vascular anomalies by an apparatus and method wherein the apparatus is delivered via catheter and comprises a sleeve with at least one peripheral conduit which is caused to assume an expanded, rigid configuration by the introduction of a chemical or mechanical hardening means, whereby the sleeve is caused to assume an open cylindrical configuration for fluid flow therethrough.
Owner:SCI MED LIFE SYST

Endovascular apparatus

InactiveUS20060276881A1Same resultStentsOcculdersVascular Skin TumorIntravascular device
Percutaneous treatment of aortic aneurysms and like vascular anomalies by an apparatus and method wherein the apparatus is delivered via catheter and comprises a sleeve with at least one peripheral conduit which is caused to assume an expanded, rigid configuration by the introduction of a chemical or mechanical hardening means, whereby the sleeve is caused to assume an open cylindrical configuration for fluid flow therethrough.
Owner:BOSTON SCI SCIMED INC

Anticoagulation Agent and Uses Thereof

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.
Owner:BAKER IDI HEART & DIABETES INST HLDG LTD

Method of diagnosing a lower urinary tract disorder

ActiveUS8010185B2High sensitivitySurgeryEndoscopesDiseaseVascular Skin Tumor
A method for sensitively diagnosing lower urinary tract disorders, particularly interstitial cystitis, is provided. The method can visually, simply, and clearly diagnose bladder ulcer without requirement of bladder hydrodistention under anesthesia. In the method, lower urinary tract disorders are diagnosed by observing an abnormality of a blood vessel and / or a newly formed blood vessel in a surface of bladder mucous membrane among abnormalities in blood vessels and / or newly formed blood vessels by visually comparing an image of the surface of the bladder mucous membrane and an image of a deep portion of the bladder mucous membrane obtained using a bladder endoscope system having a narrow band imaging device.
Owner:N M A

Optical coherence tomography system for health characterization of an eye

InactiveUS20160317026A1OthalmoscopesVascular Skin TumorOct angiography
This disclosure relates to the field of Optical Coherence Tomography (OCT). This disclosure particularly relates to methods and systems for providing larger field of view OCT images. This disclosure also particularly relates to methods and systems for OCT angiography. This disclosure further relates to systems for health characterization of an eye by OCT angiography. This OCT angiography system may determine a feature of a vasculature within an eye tissue and thereby identify a vascular anomaly and a spatial location of the vascular anomaly within the eye tissue.
Owner:UNIV OF SOUTHERN CALIFORNIA

Monitoring device and method for operating a monitoring device

A monitoring device for a patient for predicting a cardiovascular anomaly and a method for operating a monitoring device is provided. Furthermore, an implantable electrotherapy device, such as an implantable cardiac pacemaker, an implantable cardioverter, or an implantable defibrillator, having a monitoring device are also provided. In an embodiment, the monitoring device acquires a value change of a hemodynamic parameter, which occurs as a result of a detected value change of a state parameter, for example, as a result of an activation or deactivation of a cardiac resynchronization therapy. By suitable evaluation of the value change of the hemodynamic parameter, the monitoring device can output an evaluation result signal which is indicative of an imminence of a cardiovascular anomaly, such as a cardiac decompensation, long beforehand and with high specificity.
Owner:BIOTRONIK SE & CO KG

Micro-rna that promotes vascular integrity and uses thereof

InactiveUS20110196017A1Prevents vascularizationOrganic active ingredientsSenses disorderDiseaseEmbryo
The present invention relates to the identification of a microRNA, designated miR-126, that is a regulator of vascular integrity in endothelial cells. This endothelial cell-restricted microRNA mediates developmental angiogenesis in vivo, and targeted deletion of miR-126 in mice causes leaky vessels, hemorrhaging, and partial embryonic lethality, due to a loss of vascular integrity and defects in endothelial cell proliferation, migration, and angiogenesis. These vascular abnormalities resemble the consequences of diminished signaling by angiogenic growth factors, such as VEGF and FGF. These findings have important therapeutic implications for a variety of disorders involving abnormal angiogenesis and vascular leakage. Methods of treating disease states characterized by ischemia, vascular damage, and pathologic neovascularization by modulating miR-126 function are disclosed.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Application of diosgenin-3-site derivative

The invention provides an application of a diosgenin-3-site derivative shown as formula I in preparing an inhibitor for treating angiogenesis. In the formula I, R1 represents an amino linear fatty acid group or amino acid residue; R2 represents H or R3(CO)- or an acceptable salts thereof; and R3 represents H, C1-C4 alkyl or phenyl. Research results show that the diosgenin derivative shown as the formula I has a good inhibition activity for angiogenesis, and can effectively inhibit abnormal proliferation of blood vessels of eyes. Besides, the derivative has no obvious stimulation to eyes and provides novel selection for clinical medication. The formula I is shown in the description.
Owner:SICHUAN JINGHUACHUANG BIOTECH

Protein kinase inhibitors

The present invention relates to angiogenesis inhibitors, in particular receptor tyrosine kinase inhibitors, and their use for the treatment of hyperproliferative diseases, angiogenesis and disorders depending on angiogenesis such as tumour forming cancers. It also relates to a method of inhibiting angiogenesis or treating a vascular anomaly in a mammal comprising administering to the mammal an amount of an Eph receptor inhibitor which is effective for inhibiting angiogenesis or for treating the vascular anomaly in the mammal. Further, the present invention relates to the use of compounds for the treatment of angiogenesis related disorders involving a protein kinase, preferably a tyrosine kinase, and to some specific forms of said compounds as a medicament. Compounds useful in the practice of the invention have the general formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification.
Owner:ONCALIS

Medical use of ras antagonists for the treatment of capillary malformation

InactiveUS20060141472A1Restoring and normalizing downstream effectPreventing or alleviating vascular anomaliesOrganic active ingredientsMicrobiological testing/measurementVascular Skin TumorCapillary malformation
The invention relates to the field of vascular anomalies and methods for diagnosing and treating them. The invention provides for the causative gene (RASA1) and mutations therein which are useful for diagnosis of inherited capillary malformations. The invention further provides RASA1 antagonists for use in treatment of capillary malformations.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN

Application of sodium ferulic acid in preparing medicament for expanding vascellum

InactiveCN101219129AExpand the scope of medicinal useOrganic active ingredientsCardiovascular disorderVascular Skin TumorVascular dilatation
The invention provides an application of sodium ferulate - an herb extract in the preparation of vasodilators, in particular to the application in the preparation of drugs for treating hypertension, stenocardia, etc. The sodium ferulate of the invention combined with the medical excipients permitted by the pharmacodynamics can be made into a preparation. The preparation forms essentially consist of liquid preparation and solid preparation, wherein, the solid preparation essentially consists of troche, capsule (soft capsule included) and guttate pill; the liquid preparation essentially consists of oral liquid preparation and injection liquid preparation. As the second development of the traditional herb extract-- sodium ferulate, the invention has the new pharmacological action of achieving arteriectasia directly, can relax the vascular smooth muscle, thus expanding the officinal scope, which can be used for preparing drugs to treat various relevant vascular anomalies.
Owner:ZHEJIANG UNIV

Application of viral nucleic acid sequence strictly conservative area as siRNA design template

The invention relates to application of a viral nucleic acid sequence strictly conservative area as a siRNA design template. The designed siRNA sequence can be identified by a TLR (Toll Like Receptor) 3 of a cell membrane to be used as a high-efficiency exogenous ligand for activating a signal path of the TLR 3 so as to inhibit new blood vessel anomalies. The invention also relates to application of the siRNA sequence in preparing medicine for curing diseases relevant to the new blood vessel anomalies.
Owner:百源科创分子医学研究所(南通)有限公司

Application of kumata kenin in preparation of abnormal vascular proliferation inhibition medicines

The invention discloses an application of kumata kenin in preparing abnormal vascular proliferation inhibition medicines. According to the application, kumata kenin serves as an abnormal vascular proliferation inhibitor, and can be used for treating diseases such as cancers, rheumatic arthritis, diabetic blindness and systemic lupus erythematosus which are caused by internal abnormal vascular proliferation. Experiments prove that the kumata kenin has an obvious inhibition function on the abnormal vascular proliferation. Consequently, the kumata kenin can be used for preparing the abnormal vascular proliferation inhibition medicines.
Owner:KUNMING UNIV OF SCI & TECH TECH IND SALES MANAGEMENT

APE1 inhibitor and application thereof in preparation of drugs for treatment of tumors and vascular poliferative diseases

The invention belongs to the fields of molecular biology, biochemistry and etiology, and discloses an APE1 inhibitor and application thereof in the preparation of drugs for the treatment of tumors and vascular poliferative diseases. The APE1 inhibitor has a structure shown in a following formula 1, by inhibiting the activity of the redox end of APE1, the formation process of tumors is inhibited from several aspects at the same time, compared with an existing APE1 inhibitor E3330, it is presented that the APE1 inhibitor is lower in cytotoxicity and has higher antiviral activity, antiangiogenic activity and anti-cell invasion activity and the like. The APE1 inhibitor has great application prospects on the treatment of various malignant tumors such as Kaposi's sarcoma, osteosarcoma, pancreatic cancers, bladder cancers, ovarian cancers and other cancers, and other abnormal vascular proliferative diseases such as age-related macular degeneration. The formula 1 is shown in the description.
Owner:SUN YAT SEN UNIV

Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use

InactiveUS20080090750A1Peptide/protein ingredientsPeptide sourcesPlacental lactogenPlacental vascularization
The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.
Owner:RGT UNIV OF CALIFORNIA

Monitoring device and method for operating a monitoring device

A monitoring device for a patient for predicting a cardiovascular anomaly and a method for operating a monitoring device is provided. Furthermore, an implantable electrotherapy device, such as an implantable cardiac pacemaker, an implantable cardioverter, or an implantable defibrillator, having a monitoring device are also provided. In an embodiment, the monitoring device acquires a value change of a hemodynamic parameter, which occurs as a result of a detected value change of a state parameter, for example, as a result of an activation or deactivation of a cardiac resynchronization therapy. By suitable evaluation of the value change of the hemodynamic parameter, the monitoring device can output an evaluation result signal which is indicative of an imminence of a cardiovascular anomaly, such as a cardiac decompensation, long beforehand and with high specificity.
Owner:BIOTRONIK SE & CO KG

Magnetic product for refining molecular groups of both blood and water in body and application thereof

The invention relates to a magnetic product for refining molecular groups of both blood and water in a body and application thereof. The intensity of magnetism of the product adopting a magnetic material is in the range of equal to or larger than 2000 gausses. The product adopting the magnetic material provided by the invention has the advantages that the molecular groups of both blood and water in the body can be refined; the condensation of red blood cells is avoided; the effect of activating blood and dissolving stasis is achieved; the blood viscosity can be reduced; the vascular anomaly (such as sclerosis, rhexis and lumen stenosis) and cardiac anomaly (such as reducing of mental and physical efforts) can be avoided; the ability of the blood for providing oxygen and nutriment and the ability of the blood for discharging metabolic products, such as carbon dioxide, are increased; and the product adopting the magnetic material is particularly suitable for middle-aged and elderly people with fast pace of work, high pressure and declining immune functions, and can be used for preventing and treating high blood pressure, cervical spondylosis, hand and foot numbness, arthralgia, scapulohumeral periarthritis, migraine, early rheumatoid arthritis, early vitiligo, chloasma, age pigment, poor circulation of vital energy and blood, cerebral infarction, myocardial infarction and the like.
Owner:张志伟

Anticoagulation agent and uses thereof

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.
Owner:BAKER IDI HEART & DIABETES INST HLDG LTD

Treatment of skin disorders

ActiveUS11414426B2Improved profileLower immunosuppressive potentialOrganic active ingredientsOrganic chemistryMetaboliteThio-
The present invention relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then Xi, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—; with the proviso that at least one of R1 and R2 is a morpholinyl of formula II; and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis, a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.
Owner:TORQUR AG

Application of evi-1 inhibitor in preparation of medicine for treating abnormal vascular remodeling disease

The invention discloses applications of a transcription factor and an oncoprotein-ecotropic viral integration site 1 (EVI-1) inhibitor in vascular remodeling, wherein the EVI-1 inhibitor employs vascular smooth muscle specific marker gene (SMA, SM22, etc) and a specific transcription factor (SRF, Myocardin) as direct target points, thus improving expression of the smooth muscle specific gene, significantly inhibiting conversion from contractile type to secreting type of vascular medial smooth muscle cells, and further reducing abnormal regeneration of inner membrane after vascular injury. Theapplication is carried out from cell functional test into molecular mechanism researching at gene and protein levels, wherein an in-vivo animal pathological model test is converted into specimen analysis of clinical patients; all the results prove that the EVI-1 inhibitor is a key regulation factor for phenotypic transformation of smooth muscle cells; so there are reasons to believe that the EVI-1inhibitor is highly possible to be used as a novel anti-vascular anomaly remodeling medicine for treatment of cardiovascular and cerebrovascular diseases in future.
Owner:ZHEJIANG UNIV

Transgenic mouse comprising a disrupted Fibulin-4 gene as a model for cardiovascular disease

The invention relates to an animal model of cardiovascular disease and a method of preparation and use thereof. In particular, it relates to a genetically engineered animal model of aortic aneurysms and methods for screening drugs using the animal model. Provided is a genetically-modified, non-human mammal, wherein the modification results in a disrupted Fibulin-4 gene. Also provided is a genetically-modified animal cell containing a disrupted Fibulin-4 gene. The mammal or animal cell can be used as a model for a cardiovascular condition or disease, preferably aortic aneurysm, more preferably thoracic aortic aneurysm. Furthermore, methods for identify or validating a compound that can be used to treat or to prevent an aberrant cardiovascular condition are provided, as well as method to identify a gene involved in the response to aortic failure.
Owner:ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC

Method of diagnosing a lower urinary tract disorder

ActiveUS20090069696A1High sensitivitySurgeryEndoscopesVascular Skin TumorDisease
A method for sensitively diagnosing lower urinary tract disorders, particularly interstitial cystitis, is provided. The method can visually, simply, and clearly diagnose bladder ulcer without requirement of bladder hydrodistention under anesthesia. In the method, lower urinary tract disorders are diagnosed by observing an abnormality of a blood vessel and / or a newly formed blood vessel in a surface of bladder mucous membrane among abnormalities in blood vessels and / or newly formed blood vessels by visually comparing an image of the surface of the bladder mucous membrane and an image of a deep portion of the bladder mucous membrane obtained using a bladder endoscope system having a narrow band imaging device.
Owner:N M A

Application of EVI-1 inhibitor for preparing medicines for treating vascular anomaly remodeling diseases

The invention discloses applications of a transcription factor and an oncoprotein-ecotropic viral integration site 1 (EVI-1) inhibitor in vascular remodeling, wherein the EVI-1 inhibitor employs vascular smooth muscle specific marker gene (SMA, SM22, etc) and a specific transcription factor (SRF, Myocardin) as direct target points, thus improving expression of the smooth muscle specific gene, significantly inhibiting conversion from contractile type to secreting type of vascular medial smooth muscle cells, and further reducing abnormal regeneration of inner membrane after vascular injury. Theapplication is carried out from cell functional test into molecular mechanism researching at gene and protein levels, wherein an in-vivo animal pathological model test is converted into specimen analysis of clinical patients; all the results prove that the EVI-1 inhibitor is a key regulation factor for phenotypic transformation of smooth muscle cells; so there are reasons to believe that the EVI-1inhibitor is highly possible to be used as a novel anti-vascular anomaly remodeling medicine for treatment of cardiovascular and cerebrovascular diseases in future.
Owner:ZHEJIANG UNIV

Treatment of skin disorders

The present invention relates to a compound of formula (I), wherein X<1>, X<2> and X<3> are, independently of each other, N or CH; with the proviso that at least two of X<1>, X<2> and X<3> are N; Y isN or CH; W is H or F; with the proviso that when W is F, then X<1>, X<2> and X<3> are N; R<1> and R<2> are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes thebond in formula (I); and wherein R<3> and R<4> are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)0-C1- C2alkyl; or R<3> and R<4> form together a bivalent residue -R<5>R<6>- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R<7>; wherein R<7> isindependently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1- C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R<7> substituents form together a bivalent residue -R<8>R<9>- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-0-CH2- or -0- CH2CH2-0-; with the proviso that at least one of R<1> and R<2> is a morpholinyl of formula II; andprodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in a method of treating a skin disorder in a subject, wherein said skin disorder is a genodermatosis,a vascular anomaly or a skin disorder selected from scleroderma, sclerodermatous chronic graft-versus-host disease, lichen sclerosus, lichen planus, lichen ruber planus and scars.
Owner:TORQUR AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products